Navigation Links
Agarose - Separation >500 bp Genetic Performance Certified™

ProductsAgarose - Separation >500 bp Genetic Performance Certified™
Company USB Corporation
Item Agarose - Separation >500 bp Genetic Performance Certified™
Features 
Description Ultrapure
MB Grade
PRODUCT SPECIFICATIONS
Form: Granular, free-flowing powder
EEO (-mr): 0.05 - 0.13
Gel Point (1.5%): 36.0 1.5C
Remelt Point (1.5%): 88.0 1.5C
Gel Strength (1%): greater than or equal to 1,200 gm/cm2
Gel Strength (1.5%): greater than or equal to 2,500 gm/cm2
Moisture: less than or equal to 7%
Turbidity (1.5%): less than or equal to 40 Np
Residue on Ignition: 0.4%
Sulfate (SO4): less than or equal to 0.14%
Genetic Performance Tests:
DNase: Passes test
RNase: Passes test
Restriction Enzyme Digestion: Passes test
Ligation: Passes test
DNA Binding: Passes test
Blotting: Passes test
Gel Background: Passes test
DNA Resolution: Passes test
Separation Guidelines:
Range of separation in 1X TAE:
0.6%: 20,000 - 1000 bp
0.8%: 12,000 - 500 bp
1.0%: 8000 - 300 bp
1.2%: 6000 - 200 bp
1.5%: 3500 - 100 bp
2.0%: 2000 - 50 bp
Range of separation in 1X TBE:
0.6%: 15,000 - 1000 bp
0.8%: 10,000 - 500 bp
1.0%: 7000 - 250 bp
1.2%: 5000 - 200 bp
1.5%: 3000 - 100 bp
2.0%: 2000 - 50 bp

Applications:

*Separation of DNA or RNA fragments greater than or equal to 500 bp.
*PCR analysis.
*Recovery of separated DNA or RNA fragments from gel.
*Blotting applications such as Southerns and Northerns.

CAS # 9012-36-6
Info USB Corporation
Customer Service: (800) 321-9322
Web site: http://www.usbweb.com

Related medicine products :

1. LB Top Agarose 100ml Bottle
2. LB Agarose Plates
3. Agarose-HR™
4. Agarose for the Separation of GeneAmp® PCR Products
5. Certified PCR Agarose
6. Certified Molecular Biology Agarose
7. Certified Low Range Ultra Agarose
8. Certified Megabase Agarose
9. Agarose, Type C
10. SeaKem® GTG® Agarose
11. Agarose, separation > 500 bp, Genetic Performance Certified †
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches.
2.0 mm cup. Angled 45 degree shaft 8 mm from tip to bend with flat handle and polished finish. Overall length: 4.8 inches.
Round, knurled handle with polished finish and straight shaft. 1 mm ring curette 1.5 mm high, 33 mm shaft. Overall length: 5.1 inches.
0.5 mm curette cup, reverse side of sandblasted to polish capsule. Round knurled handle with polished finish. Overall length: 5 inches.
Medicine Products:
(Date:9/5/2008)...USTON - Lung cancer risk prediction models are enh...and by measuring DNA repair capacity, according to...ersity of Texas M. D. Anderson Cancer Center in tw...issue of Cancer Prevention Research . , In the ...hers found unique results based on increased expos...
(Date:9/4/2008)...New York, NY, September 5, 2008Private Medicare Ad...rcent more per enrollee in 2008 compared to what t...l Medicare fee-for-service program, according to a...he payment reductions to MA plans mandated by the ...ct of 2008 (MIPPA) scheduled to take effect begin...
(Date:9/4/2008)...ings of 3 studies focus on brain and pancreatic tu...ws) -- Potentially groundbreaking discoveries invo...he brain cancer glioblastoma and pancreatic cancer...earchers say. , "These studies represent the m... type and provide a detailed genetic map of these ...
(Date:9/4/2008)...PACIFIC PALISADES, Calif., Sept. 4 /PRNewswire/ --...recognized authority in the field of weight,contro...s Who in,California," "Who,s Who in The West," "Wh...o,s Who in Medicine and Health Care" and other hon...his expertise to exposing the,inaccurate, misleadi...
Breaking Medicine News(10 mins):Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2
...ople in the United States are on waiting lists for... death of a matching donor, but more and more peop...t year nearly 7,000 people donated a kidney, segme...elp someone in need of a transplant. In fact at so...
...diabetics in China is smaller than that of many ot...na had around 23.8 million diabetics// of age betw...tween 40 and 59 are increasing in China, while dia...9 in developed countries," said Guo Xiaohui,who he...
...s the fourth leading cause of cancer deaths in the...ually affected // It is one of the most deadly ca...it has spread to other parts. Only about five perc...atients survive the first five years after being d...
...esting based on the ‘survival of the fittest’ theo...th a motive to nurture// the healthy ones, has bor...Couple, the first in UK, after successfully employ... This method proved a blessing to the parents in ...
Other Medicine News:Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 3
(Date:9/4/2008)...tion for Targeted Therapies That Ensu...N BEACH, Calif., and AMSTERDAM, Netherlands, Sept....cular cancer diagnostics,today announced the laun...llows physicians to quantitatively determine the g...), progesterone receptor (PR) and Human Epidermal,...
(Date:9/3/2008)...Children Studied. Wrong,Conclusions Reached., NIX...rs for Disease,Control and Prevention (CDC) study ... MMR vaccine and autism. The National Autism Assoc...l the growing public concern over a,vaccine-autism...g design,and methodology., For years, parents hav...
(Date:9/3/2008)...ronically infected Hepatitis C,patients strongly c...n 2008, - Study is the first to show a statistic...fect of therapeutic Hepatitis C vaccination, - D...second generation, vaccine formulated with Interc... activation, VIENNA, Austria...
(Date:9/3/2008)...e/ -- Panacea Pharmaceuticals,Inc. today announce...ering,antibodies against human aspartyl (asparagin...ancer biomarker and therapeutic target. These anti...ssachusetts Institute of,Technology (MIT) and Pana...,for development of human cancer diagnostics and t...
Breaking Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Jury Rules in Favor of Glycoproducts International Inc 20365 1Jury Rules in Favor of Glycoproducts International Inc 20365 2Photos 3A Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5 Year Old Blind Iraqi Girl Whose Father Stands 20360 1Photos 3A Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5 Year Old Blind Iraqi Girl Whose Father Stands 20360 2Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 1Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 2Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 3Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 4Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 5Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 6Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 7Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 8Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 9Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 10Human Genome Sciences Reports Progress With Late Stage Products and New Initiatives 2200 11Researchers from 5 countries to test hygiene hypothesis with EU funding 20355 1Researchers from 5 countries to test hygiene hypothesis with EU funding 20355 2
...urne, Australia — 19 April 2007- Biota Holdi...g acting,neuraminidase inhibitor (LANI), CS8958, a...d effectiveness against the avian flu virus,H5N1; ...ceived ethics approval to commence comparable stud...Daiichi-Sankyo, overnight announced,that laborator...
...nnounces Positive Top-Line Phase III Results for,K... Seizures in,Paediatric Patients from One Month to... April 20, 2007 - UCB today announced,positive top...omized, multi-centre, placebo-controlled study eva...g; (levetiracetam) (20-50,mg/kg/day) as adjunctive...
Other Medicine Technology:LANI completes Phase I in Japan and to commence Phase I in UK 2LANI completes Phase I in Japan and to commence Phase I in UK 3LANI completes Phase I in Japan and to commence Phase I in UK 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5